Firebrick Pharma says Nasodine Phase 2 COVID-19 trial results published

Latest News

Firebrick Pharma (ASX:FRE) has announced that its Phase 2 COVID-19 trial has been published in the journal, Laryngoscope.

The paper is titled 'Phase II Trial of the Impact of 0.5% Povidone-Iodine Nasal Spray (Nasodine) on Shedding of SARS-CoV-2.

The company reported the trial's headline results in August last year, highlighting that it achieved its primary endpoint with Nasodine treatment, significantly reducing the nasal viral load of SARS-CoV-2.

It said that the nasodine treatment also led to a 100 per cent clearance of the virus from the nose after the completion of the treatment.

The published paper said, “The Phase II data demonstrate that frequent dosing with a 0.5% PVP-I intranasal formulation (Nasodine) can reduce the titers of culturable SARS-CoV-2 virus recovered from a subject's upper respiratory tract. Nasodine is the only PVP-I nasal spray that has been manufactured at scale in accordance with GMP, with established stability, and with proven safety and tolerability in multiple human clinical trials. It is therefore amenable to rapid deployment as a readily administered intervention in the face of emergent pandemic/epidemic respiratory
threats such as COVID-19.”

“This published paper is an important endorsement of the quality and significance of the trial,” said executive chairman Dr Peter Molloy. “The demonstrated reduction in viral load and 100% clearance of an important respiratory virus should be highly supportive of the potential for Nasodine as a nasal antiseptic/disinfectant.”

Firebrick said it is now advanced in its plans to introduce Nasodine in at least one international market, with sales expected to commence in the first half of 2024.